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 Abstract 11 
Pharmaceutical consumption has expanded rapidly during the last century and their persistent 12 
presence in the environment has become a major concern. Unfortunately, our understanding of 13 
the distribution of pharmaceuticals in surface water and their effects on aquatic biota and 14 
public health is limited. Here, we explore patterns in the detection rate of the most frequently 15 
studied pharmaceuticals in 64 rivers from 22 countries using bi-clustering algorithms and 16 
subsequently analyze the results in the context of regional differences in pharmaceutical 17 
consumption habits, social and environmental factors, and removal-efficiency of wastewater 18 
treatment plants (WWTP). To our knowledge, this is the first study to compare several rivers 19 
across 3 major continents and systematically analyze them in this framework. We find that 20% 20 
of the pharmaceuticals included in this analysis are pervasively present in all the surface 21 
waterbodies. Several pharmaceuticals also display low overall positive detection rates; 22 
however, they exhibit significant spatial variability and their detection rates are consistently 23 
lower in Western European and North America (WEOG) rivers in comparison to Asian rivers. 24 
Our analysis suggests the important role of pharmaceutical consumption and population in 25 
governing these patterns, however the role of WWTP efficiency appeared to be limited. We 26 
were constrained in our ability to assess the role of hydrology, which most likely also plays an 27 
important role in regulating pharmaceuticals in rivers. Most importantly though, we 28 
demonstrate the ability of our algorithm to provide probabilistic estimates of the detection rate 29 
of pharmaceuticals that were not studied in a river, an exercise that could be useful in 30 
prioritizing pharmaceuticals for future study. 31 
.   32 
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1. Introduction 33 
Pharmaceutical consumption has increased drastically in the last 50 years and is likely to 34 
continue increasing in the coming years due to rising population, changing demographic across 35 
the globe, and growing availability across the world (Daughton, 2003). The presence of 36 
pharmaceuticals and their metabolites in environmental matrices is well established and is a 37 
major environmental concern (Beek et al., 2016; Daughton, 2001; Jones et al., 2001; Oaks et al., 38 
2004; Schwarzenbach et al., 2006) . However, there are considerable knowledge gaps on the 39 
impacts of pharmaceuticals on aquatic organisms and ecosystems(Botitsi et al., 2007; Brain et 40 
al., 2008; Daughton, 2001; Kümmerer, 2009a, 2009b; Santos et al., 2007). With increasing use 41 
of gray water in agriculture and in recharging groundwater for future human consumptions , 42 
there are also growing concerns on the long-term effects of persistent exposure to 43 
pharmaceuticals on public health (de Jesus Gaffney et al., 2015; Grossberger et al., 2014; Jones-44 
Lepp et al., 2012; Webb et al., 2003). Many countries and environmental agencies have 45 
recognized their potential detrimental effects and are developing policies to mitigate their 46 
impacts (Kaplan, 2013; Peake et al., 2015; Walters et al., 2010). 47 
To evaluate the potential eco-toxicological risks of pharmaceuticals, it is important to measure 48 
or model (Amiard-Triquet et al., 2015; Huggett et al., 2003; Johnson et al., 2013; Kehrein et al., 49 
2015; Kostich and Lazorchak, 2008)  their concentration in environmental compartments, 50 
document their spatiotemporal variability and understand the role of environmental and social 51 
factors in determining their presence in the environment. However, there are more than 3000 52 
pharmaceuticals consumed in Europe alone (Donnachie et al., 2016) and exhaustive monitoring 53 
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of all the pharmaceuticals (and their metabolites) is expensive and impractical. In this regard, 54 
statistical analysis (such as meta-analysis, clustering, regression) of large pharmaceutical 55 
datasets could be useful in identifying spatiotemporal patterns of pharmaceuticals and their 56 
relationship with environmental covariates. This information could then be used to prioritize 57 
pharmaceuticals for future studies, assess relationships between pharmaceuticals (for example: 58 
which pharmaceuticals always co- occur in a river and which do not), examine pharmaceutical 59 
detection patterns across regions, and identify other questions relevant to the risk of 60 
pharmaceuticals in surface water (Altenburger et al., 2003; Andrews, 2001; Donnachie et al., 61 
2016; Jones et al., 2002; Kostich and Lazorchak, 2008; Kumar and Xagoraraki, 2010; Rehman et 62 
al., 2015). It is however worth mentioning that for each pharmaceutical, a minimum number of 63 
analytical measurements is indeed required to understand the relationships between different 64 
pharmaceuticals. 65 
Here, we systematically analyze the detection rate (how often a pharmaceutical was positively 66 
detected when analyzed) of the 112 most commonly studied pharmaceuticals in 64 rivers from 67 
22 countries using a stochastic block model (also known as a co-clustering or bi-clustering 68 
model). Briefly, stochastic block model (SBM) is used for clustering high-dimensional data, 69 
where the algorithm simultaneously clusters rows and columns of the data to obtain subgroups 70 
of rows and subgroups of columns that exhibit a high correlation (Berkhin, 2006; Govaert, 1995; 71 
Hartigan, 1972; Tanay and Sharan Ý Ron Shamir, 2004). A salient feature of the algorithm is its 72 
ability to perform robustly even with substantial missing data. The algorithm has been used for 73 
analyzing high-dimensional data in many fields, including bioinformatics (Tanay and Sharan Ý 74 
Ron Shamir, 2004), text-mining (Dhillon, 2001), ecology (Chi et al., 2017; Hill et al., 2013), and 75 
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social network analysis (Banks and Hengartner, 2008; Hoff et al., 2002). Figure 1 provides a 76 
hypothetical example to illustrate how the algorithm works. For detailed information on SBM 77 
and/or co-clustering please refer to (Berkhin, 2006; Govaert, 1995.; Hartigan, 1972). 78 
To our knowledge this is the first study to 1) systematically analyze the spatial patterns in the 79 
detection rates of the most commonly studied pharmaceuticals, 2) analyze the role of social 80 
and environmental factors, such as wastewater treatment plant (WWTP) efficiency, 81 
pharmaceutical consumption habits, population density and hydrological factors, in 82 
determining the pattern of pharmaceutical detection rates and 3) estimate the occurrence 83 
probability of unanalyzed pharmaceuticals to support analyte prioritization for future study. 84 
2. Methods 85 
2.1 Description of the database and data aggregation 86 
We obtained the pharmaceutical data analyzed in this study from the Measured Environmental 87 
Concentration (MEC) database maintained by the German Environmental Agency (UBA, 88 
https://www.umweltbundesamt.de/en/database-pharmaceuticals-in-the-environment-0). The 89 
database, accessed on 10/01/2018, consists of 123,761 entries of pharmaceuticals and/or their 90 
transformation products measured in environmental matrices such as surface water, 91 
groundwater, drinking water and WWTP effluent across 71 countries. To our knowledge, this is 92 
the most comprehensive global dataset on pharmaceuticals available. For details on the 93 
database please refer to UBA website and Beek et al., (2016). Majority of the data in the 94 
database were from 2001 to October 2013. Only 1281 entries in the database predated 2001 95 
and there were no entries after October 2013. 96 
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2.2 Rationale for analyzing detection rates of pharmaceuticals 97 
Instead of analyzing measured concentrations reported in the literature from where the data 98 
were obtained, we transformed the data into presence/absence format for several reasons. 99 
First, the majority of the studies measuring pharmaceuticals during the last two decades have 100 
not followed internationally/regionally established protocols (Ort et al., 2010) with minimal 101 
information on uncertainty associated with the measurements. Second, most of the 102 
pharmaceuticals included in our analysis have been measured less than 5 times on a river with 103 
limited or no information on the prevailing hydrological conditions. As a consequence, using a 104 
statistical estimate (such as mean or mode) can lead to incorrect characterization of the 105 
concentration if all the measurements were done only within a single hydrologic regime (for 106 
e.g. river low-flow season). Finally, several studies often report different summary statistics 107 
(e.g., mean, median or maximum concentration), typically based on very different sample sizes, 108 
hindering a straight-forward comparison of these concentration values. Due to these 109 
limitations, we believe that reducing the data to present/absent format was the most reliable 110 
and robust way to minimize measurement uncertainties while capturing the majority of the 111 
data published over the last two decades.  112 
2.3 Rationale for analyzing pharmaceutical data on basin scale instead of 113 
national scale   114 
While there have been previous global, continental and country level analyses on river systems 115 
to identify and understand spatiotemporal variability in pharmaceutical occurrence (Barnes et 116 
al., 2008; Hughes et al., 2013; Jiang et al., 2013; Klečka et al., 2009; Loos et al., 2010), none to 117 
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our knowledge have performed statistical analysis to explore global patterns in pharmaceutical 118 
occurrences in surface waterbodies and understand the factors determining these patterns. A 119 
primary motivation for basin-scale data analysis was the high variability in data availability 120 
between national datasets with some countries (such as Germany or USA) having an order of 121 
magnitude or more data than others. Importantly, pharmaceutical measurements when 122 
organized by river basins are more evenly distributed and less skewed (supplementary material, 123 
Figure S1), thus allowing more robust statistical comparisons.  124 
2.4 Statistical analyses 125 
2.4.1 Pharmaceutical Contamination Index 126 
For each river i, we calculated the mean detection rate or River Contamination Index (RCI) using 127 
the following formula 128 
 𝑅𝐶𝐼𝑖 =  1𝑛𝑖 ∑ 𝑃𝑖,𝑗𝑇𝑖,𝑗𝑛𝑖𝑗=1  129 
where 𝑃𝑖,𝑗  and 𝑇𝑖,𝑗are the number of times pharmaceutical j was positively detected and 130 
measured at river i, respectively. In this expression, 𝑛𝑖  is the number of unique pharmaceuticals 131 
measured at river i. An RCI value of 1 means that all pharmaceutical analytes assessed in river i 132 
were detected and a value of 0 means that none of the pharmaceuticals measured at river i 133 
were ever detected.  134 
2.4.2 Stochastic Block Model 135 
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For each river, we determine the number of times a pharmaceutical was analyzed and 136 
positively detected. We arranged our data in a format where each row represents a river and 137 
each column represents a unique pharmaceutical. The model groups together rivers and 138 
pharmaceuticals that have similar detection rate and output subgroups (also called blocks) that 139 
are similar. We used SBM in our analysis as it not only allows us to identify rivers groups and 140 
pharmaceutical clusters with similar detection rates but also provides information on their 141 
covariation that can be used for prediction. Additionally, the generative nature of SBM allows 142 
computing the mean probability (together with the associated uncertainty) of positively 143 
detecting pharmaceuticals for each” river and pharmaceutical block”. In other words, the 144 
model provides us the probability (with uncertainty) of detecting unmeasured pharmaceuticals 145 
in a river. The detailed process of sub-setting data from the MEC database, its subsequent 146 
manipulation for analysis and a complete description of our algorithm are provided in the 147 
supplementary material. We provide an illustrative example of our data formatting and its 148 
subsequent rearrangement by SBM in Figure 1. Since the algorithm groups rivers as well as 149 
pharmaceuticals (see Figure 1), we refer to pharmaceutical groups as ‘pharmaceutical clusters’ 150 
to avoid confusion with river groups.  151 
Similar to the river, we determined the number of times a pharmaceutical was analyzed and 152 
positively detected in WWTPs (Influent and effluent). Pharmaceuticals that were measured in 153 
WWTP but were not part of our river subset samples were discarded. To explore continental 154 
scale differences, we subdivided the WWTP detection rates in three UN groups (Asia, Eastern 155 




2.5 Social and environmental variables 158 
We explored the effect of environmental and anthropogenic factors (e.g., watershed size, river 159 
length, flowrate and population density) on the degree of contamination for the different 160 
rivers. We specifically chose these variables as it has been shown that they can play an 161 
important role in governing the degree of contamination of the rivers (Acuña et al., 2015; Burns 162 
et al., 2018; Kaushal and Belt, 2012; Osorio et al., 2016, 2012a; Peng et al., 2008). We obtained 163 
the corresponding information for each river basin from published literature and reports from 164 
national agencies. For the few rivers with no published data on population, we estimated basin 165 
population by clipping the global population estimates, obtained from the Center for 166 
International Earth Science Information Network (Columbia University), with river shape files 167 
obtained from HydroSHED (Lehner et al., 2008) and European Environmental agency.  168 
3. Results  169 
Our methodology resulted in 2202 measurements of 112 pharmaceuticals across 64 rivers 170 
(Figure S2) with 1324 positive observations resulting in a mean detection rate of 60%. The 171 
range of RCI varied between 0 and 1. Except for 1 river with measurements between 30-50 172 
samples (Figure 2), very low RCI values were generally associated with rivers with a lower 173 
number of measurements (Figure 2) suggesting that sample size might play a role in governing 174 
the RCI.  Indeed, for rivers with less than 50 measurements, the range of RCI was large (0 to 1). 175 
On the other hand, for rivers, with greater than 50 measurements RCI ranged from 0.3 to 0.85 176 
(Figure 2), revealing that as the number of measurements increases, extreme low RCI values are 177 
unlikely and thus every river would exhibit some degree of contamination if pharmaceuticals 178 
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are measured with adequate intensity. This suggest that the limited monitoring of 179 
pharmaceuticals in waterbodies, compared to a more traditional pollutants, may lead to 180 
inaccurate conclusions on their presence or absence, and concentrations, and that further, 181 
more spatially and temporally intensive, monitoring is needed.  182 
The stochastic block model (SBM) resulted in 6 pharmaceutical clusters and 5 river groups 183 
respectively (Figure 3) i.e. 30 (6 multiplied by 5) blocks of rivers and pharmaceuticals. Each 184 
block consists of a set of rivers that have similar detection rates for a set of pharmaceuticals. 185 
Each block can also be considered as a set of pharmaceuticals that have similar detection rates 186 
for a set of rivers. The effectiveness of the model in grouping surface waterbodies as well as 187 
pharmaceuticals with similar detection rates is best realized by visually comparing the data 188 
before and after clustering (see Figure S3 for the raw un-clustered data).  The pharmaceutical 189 
clusters and the river groups are arranged in increasing order of the detection rates.  190 
Pharmaceuticals in clusters D to F were positively detected in all the river groups and 191 
pharmaceuticals in clusters A and B were mostly undetected in river groups 1 to 3 (Figure 3). 192 
We also observe regional differences in the river groups. All but two Asian rivers were assigned 193 
to river groups 4 and 5 which exhibited high detection rates, suggesting highest level of 194 
contamination in Asian Rivers. European and North American rivers were present in all the 195 
groups, however our model also revealed important differences within the European rivers. 196 
Only German and Slovenian rivers belonged to river groups 1 and 2, with very low detection 197 
rates of cluster A pharmaceuticals (<10%, Figure 3). In contrast, the detection rate of cluster A 198 
pharmaceuticals for Italian, Spanish and French rivers (belonging mostly to river groups 3, 4 and 199 
5, Figure 3) were ~35% which, although lower than the detection rate in Asian rivers (>80%), 200 
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was still higher than the rivers flowing in Germany, Slovakia and Netherlands (<20%). None of 201 
the cluster A pharmaceuticals (more than 20 different pharmaceuticals) that were measured 202 
multiple times in the River Rhine (flows through Switzerland, Germany and the Netherlands) 203 
were positively detected (Figure 3). 204 
Our result suggests that for all the rivers groups, the mean probability of positively detecting 205 
the pharmaceuticals in cluster F was high (Figure 4). As a result, pharmaceuticals in cluster F are 206 
likely to be positively detected in all of the studied rivers. Similarly, except for rivers in group 1, 207 
the mean likelihood of positively detecting clusters D and E pharmaceuticals in unmeasured 208 
rivers is greater than 50%. In contrast, the detection rates of clusters A to C pharmaceuticals in 209 
river groups 1 and 2 is low (Figure 4). 210 
The estimated 95% credible intervals provide confidence in interpreting the mean detection 211 
rate associated with each river and pharmaceutical block. The narrow 95% credible intervals 212 
(CIs, ranging mostly from 0.6 to 1) associated with cluster F for all the river groups (Figure 4) 213 
suggests high confidence in the likelihood of positively detecting cluster F pharmaceuticals at all 214 
the rivers. On the other hand, the 95% CI associated with clusters C and D are large (Figure 4) 215 
(due to limited number of measurements) indicating substantial uncertainty associated with 216 
these probabilities (Figure 4).  217 
4. Discussion 218 
4.1 Pattern in pharmaceutical detection rates 219 
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The high detection rates of 22 pharmaceuticals in clusters D to F (Figure 3) suggests that these 220 
pharmaceuticals were present ubiquitously in all the rivers included in this study. Many 221 
pharmaceuticals in clusters D to F are among the most widely consumed in the USA, UK and 222 
several other countries (Fuentes et al., 2018; Letsinger and Kay, 2019) and have exhibited high 223 
detection frequencies in previous global analyses of pharmaceuticals in surface water bodies 224 
(Fekadu et al., 2019; Hughes et al., 2013). The pharmaceuticals included by our model in 225 
clusters D to F do not belong to a single therapeutic group but come from diverse classes 226 
including analgesics, antibiotics, estrogens and beta-blockers (Table S1).  227 
Even though the overall detection rate of pharmaceuticals in clusters A, B and C (Figure 3) was 228 
lower, the detection rate for pharmaceuticals in these clusters were not similar across the river 229 
groups. Blocks 4-A, 5-A 3-B, 4-B and 5-B had much higher positive detection than blocks 1-A, 2-230 
A, 3-A, 1-B and 2-B (see figure 3). Most of the rivers with high detection rates of 231 
pharmaceuticals in clusters A and B were Asian. Among the European rivers, only Italian, French 232 
and Spanish exhibited high detection rates. Rivers from other European countries including 233 
England, Germany, Netherlands and Slovakia exhibited low detection rates for pharmaceuticals 234 
in clusters A and B. Our model output suggests, there are systematic country level differences 235 
in the rivers for clusters A and B pharmaceuticals. These differences might be attributable to 236 
multiple factors (e.g., pharmaceutical consumption pattern, WWTP removal processes, 237 
hydrological and social factors and/or a combination of these factors), that we discuss below.  238 
4.2 Factors governing the regional differences among the rivers  239 
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To explore the patterns observed above, we combined the rivers into their official UN regional 240 
group resulting in 13, 10 and 41 rivers belonging to Asia, Eastern Europe (EE) and Western 241 
Europe and others (WEOG) regional groups, respectively. For the WEOG group, 33 rivers were 242 
Western European and 8 were North American. We also combined pharmaceuticals in clusters 243 
A to C and D to F respectively in 2 groups as pharmaceuticals in clusters A to C and D to F have 244 
similar detection rates. We restrict our discussion to Asian and WEOG groups as the majority of 245 
the rivers in the EE group are from a single country (Slovakia, see Figures 3 and S2). 246 
4.2.1 Wastewater treatment plants 247 
In developed countries, WWTP effluent is considered a primary source of pharmaceuticals to 248 
aquatic environments (Andreozzi et al., 2003; Letsinger and Kay, 2019; Petrovic et al., 2002) and 249 
the degree of contamination of a river is linked to the pharmaceutical removal efficiency of 250 
WWTPs. In developing countries, untreated effluent could also be discharged directly due to 251 
absence of WWTPs and/or limited connectivity between houses and WWTPs. The removal rate 252 
of pharmaceuticals in WWTP varies significantly (Khamis et al., 2011; Verlicchi et al., 2012). 253 
Many of the clusters D to F pharmaceuticals such as diclofenac, acetylsalicylic acid, naproxen, 254 
and gemfibrozil are in ionic state at neutral pH, and therefore difficult to remove during waste 255 
water treatment processes (Khamis et al., 2011). In an extensive review, (Verlicchi et al., 2012) 256 
showed that the removal rate of several clusters D to F pharmaceuticals such as 257 
carbamazepine, sotalol, sulfamethoxazole, metoprolol, erythromycin and others are as low as 258 
40% even post-secondary treatment.  In contrast, many of the pharmaceuticals in clusters A to 259 
C including doxycycline, chlortetracycline, estradiol, paroxetine, sulfamethizole etc. have been 260 
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shown to have higher removal rates (Verlicchi et al., 2012). The median removal rate of clusters 261 
A to C and D to F pharmaceuticals complied in Verlicchi et al (2012) is 62% and 48% respectively 262 
(see Figure S4). It is therefore possible that the patterns observed in our pharmaceutical 263 
clusters are related to their removal efficiency by WWTP. Since WWTP are more extensive and 264 
up to date in WEOG (includes secondary and tertiary treatment processes), we hypothesized 265 
that the differences in the detection rate for cluster A to C pharmaceuticals between Asian and 266 
WEOG rivers could be due to more efficient removal of clusters A to C pharmaceuticals in 267 
WEOG.   268 
For Asia as well as WEOG groups, the detection rates of pharmaceuticals in clusters D to F were 269 
high for both WWTP influent and effluent, with little difference between Asian and WEOG 270 
effluents (Figure 5c and 5d). This was not surprising as clusters D to F pharmaceuticals are 271 
difficult to remove using conventional WWTP processes(Verlicchi et al., 2012). As expected, for 272 
pharmaceuticals in clusters A to C, the median detection rates in WWTP effluent were lower 273 
than the influent detection rates for both Asia and WEOG groups (Figures 5a and 5b) suggesting 274 
that WWTP processes are more successful in removing these pharmaceuticals than D to F 275 
pharmaceuticals. However, the decrease in the detection rate from influent to effluent were 276 
not statistically different (t-test, p>0.05) for Asian and WEOG WWTP effluents. Therefore, our 277 
first order comparative analysis does not provide any compelling indication that there are 278 
systematic differences between the WWTPs in Asia and WEOG, or that WEOG WWTPs are 279 
removing pharmaceuticals more effectively compared to the Asian WWTPs. It is possible that 280 
WEOG WWTPs are better at lowering the concentration; however, our analysis suggests that 281 
even in that case, the concertation are high enough for the pharmaceutical to be detected in 282 
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WWTP effluents. A meta-analysis of pharmaceutical concertation in WWTP influent and 283 
effluent across the different countries can provide more detailed insight into these differences. 284 
We observe a substantial decrease in the detection rates of cluster A to C pharmaceuticals 285 
between WWTP effluents and downstream river sites for WEOG (Figure 5a) but not for Asia 286 
(Figure 5b). The higher detection rates in rivers compared to the WWTP effluent for Asia 287 
suggests additional input through combined sewer overflows and/or direct discharge of 288 
untreated sewage water to the rivers. Indeed, the degree of connectivity of households to 289 
WWTP in Asia are significantly lower compared to the WEOG and the observed pattern is not 290 
surprising and highlights the need of reducing discharge of untreated wastewater in rivers and 291 
other surface waterbodies in Asia (Isobe et al., 2004; Shrestha and Pandey, 2016; Thomes et al., 292 
2019). 293 
It would have been interesting to divide European WWTPs in two subgroups that included 294 
Germany, Netherlands, Austria, Switzerland, Belgium and England in one group and  France, 295 
Italy, Spain, Portugal and Greece in another, as the countries in latter group had less than 40% 296 
of the population served by WWTP with tertiary treatment process before 2005 297 
(https://www.eea.europa.eu/data-and-maps/indicators/urban-waste-water-treatment/urban-waste-298 
water-treatment-assessment-4) whereas more than 80% of the population in Germany, 299 
Netherlands, Austria, Switzerland, Belgium and England were served by WWTPs with tertiary 300 
treatment processes by 2005. However, due to limited WWTP samples, we did not further 301 
subdivide WEOG WWTPs data in subgroups. Given the fact that most European WWTPs have 302 
upgraded to tertiary treatment in recent years, and there have been large number of studies in 303 
recent years an analysis comparing detection rates in WWTP pre and post 2010 in Europe can 304 
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help to understand and document the effectiveness of the advanced techniques in removing 305 
pharmaceuticals and perhaps explain the differences in degree of contamination of European 306 
rivers. 307 
4.2.2 Regional variation in pharmaceutical consumption 308 
The majority of the pharmaceuticals in clusters A to C are antibiotics (48 out of 85, Table S2) 309 
and their consumption varies significantly across the globe. Indeed, antibiotics are used less 310 
often and are generally more difficult to obtain without prescription in WEOG whereas their 311 
consumption in Asia is widespread and they are easily available and often unregulated (Komori 312 
et al., 2013; Shimizu et al., 2013). Between 2000 and 2010, global antibiotic consumption 313 
increased by 35%, fueled dominantly by Asian countries (Van Boeckel et al., 2014) with India 314 
and China being the largest consumers. In comparison, the consumption of antibiotics was not 315 
only lower in European countries, but also declined (“Antimicrobial consumption - Annual 316 
Epidemiological Report for 2017,”; Van Boeckel et al., 2014).  317 
As mentioned previously, the majority of the rivers in groups 1 and 2 were German and 318 
Slovenian, whereas rivers in France, Italy and Spain belonged to groups 3 to 5. According to the 319 
latest OCED (Organization for Economic Co-operation and Development) report (2017), Italy 320 
and France are among the highest consumers of antibiotics in Europe. The defined daily dose 321 
(DDD) of antibiotics in Italy and France are approximately three times higher than Netherlands 322 
and twice that of Germany and Slovenia. For this reason, we believe that the pattern observed 323 
for pharmaceuticals in clusters A to C with much higher detection rate in Asia and some 324 
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European countries in part reflect the regional and country level variation in consumption of 325 
these pharmaceuticals.  326 
4.2.3 Effects of hydrologic and socio-environmental factors 327 
The differences observed in the detection rates among the rivers could also be due to local 328 
hydrological factors. The presence of pharmaceuticals will vary in rivers due to the prevailing 329 
hydrological conditions at the time of sampling. For instance, high river flows may dilute 330 
pharmaceutical residues emanating from wastewater treatment plants. Conversely, untreated 331 
effluent could be released from combined sewer overflows during storm events. Unfortunately, 332 
these hydrological characteristics are seldom described in published reports and scientific 333 
articles. Although pharmaceutical measurements in rivers are traditionally taken during low 334 
flow summer conditions close to the WWTP effluent outlet, many pharmaceutical datasets 335 
comprise a small number of samples taken with no consideration of flow conditions. As a result, 336 
our study, which focuses on general trends at large spatial scales based on a meta-analysis, 337 
unfortunately cannot account for how flow conditions may have affected the presence of 338 
pharmaceuticals in rivers. Nevertheless, it is important to note that it would be unlikely that 339 
high flow events would have discriminately diluted pharmaceuticals in clusters A to C in WEOG 340 
to an extent that they were not detected with a similar dilution effect missing for 341 
pharmaceuticals in clusters D to F.  342 
Keeping in mind the limitations of data available and the lack of detailed information associated 343 
with sampling events, we analyzed the relationship between basin size, river length and mean 344 
flow rates and river contamination index (RCI) of the river. These hydrologic metrics were 345 
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available (or obtained) for most of the basins, however our analysis did not result in any 346 
statistically meaningful relationship between RCI and these metrics. Indeed, many of the rivers 347 
in group 1 (most contaminated) and group 5 (least contaminated) were rivers with comparable 348 
mean flow rate and size. Whereas hydrology is a critical factor in determining the degree of 349 
contamination of a river as highlighted by several studies (Kay et al., 2017; Keller et al., 2014; 350 
Kolpin et al., 2004), the lack of relationship between mean flow rate and the detection rates 351 
highlights the complexity of interaction between hydrology and pharmaceuticals in water and 352 
the inability of seasonally and basin averaged mean flow values to capture this relationship. Our 353 
analysis highlights the need for long-term catchment scale spatiotemporal studies to 354 
understand these relationships. 355 
We observe an increasing trend in RCI with increasing population density within the basin 356 
(Figure 6) albeit with significant variability. Most of the pharmaceuticals analyzed in our study 357 
were used primarily for human consumption and the positive trend between population 358 
density and pharmaceutical detection was expected. The effect of population on the degree of 359 
contamination was appropriately highlighted for the rivers Ebro, LLobregat and Ter. These 360 
rivers are comparable in size, situated within the Iberian Peninsula, Spain (thus experiencing 361 
similar climatic regime and country level pharmaceutical policies) and have more than 30 362 
unique measurements on each river. In our analysis, the detection of pharmaceuticals was 363 
much lower for the River Ter (RCI = 0.25) compared to the Llobregat (RCI = 0.78) and Ebro (RCI = 364 
0.80) which might be due to the lower population density of the River Ter (Céspedes et al., 365 
2006). A recently conducted independent study (Osorio et al., 2016) within the same region 366 
comparing four rivers (Llogregat, Ebro, Jucar and Guadalquivir) also highlighted the positive 367 
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correlation between human population and pharmaceutical concentration in  these rivers and 368 
showed that the degree of contamination of the LLobregat and Ebro were higher than Jucar and 369 
Guadalquivir, most likely due to their higher population density (Osorio et al., 2016).  370 
The presence of substantial scatter around the relationship between RCI and population density 371 
in our analysis could be due to multiple factors that can vary on basin, local and national scales 372 
including access to pharmaceuticals, pharmaceutical consumption habits, mean age of the 373 
population, seasonal variability, per capita domestic water consumption, and sampling 374 
strategies (Murata et al., 2011; Osorio et al., 2012b). Our result highlights the relationship 375 
between contamination and population and the growing need to quantify the presence of 376 
pharmaceuticals in densely populated areas especially in developing countries where public 377 
health and aquatic ecosystems might be acutely affected due to elevated presence of several 378 
pharmaceuticals. 379 
4.4 A novel approach for selecting pharmaceuticals to be studied in rivers 380 
Currently, more than 3000 pharmaceuticals are being used globally (Donnachie et al., 2016) and 381 
the list is growing. Given that our understanding of the eco-toxicological effects of most 382 
pharmaceuticals in surface water is not fully developed(Fent et al., 2006) , it is important to 383 
determine their environmental concentration. However, monitoring or modelling concentration 384 
of pharmaceuticals in surface water is challenging due to limited resources, time and costs 385 
associated with these studies. Most monitoring efforts have been limited to fewer than 10 386 
pharmaceuticals per study (Gros et al., 2006). To circumvent these challenges, researchers have 387 
complemented field measurements with estimated concentrations in surface water using 388 
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pharmaceutical sales and wastewater production rates and have developed ranking schemes to 389 
prioritize pharmaceuticals for analysis in a given location (Al-Khazrajy and Boxall, 2016; 390 
Berninger et al., 2016; Bu et al., 2020; De Voogt et al., 2009; Fick et al., 2010; Huggett et al., 391 
2003; Kostich and Lazorchak, 2008; Kumar and Xagoraraki, 2010; Sui et al., 2012),  the output of 392 
such models varies substantially (Roos et al., 2012)  limiting their utility for analytical 393 
prioritization purposes.  394 
The SBM enables the identification of pharmaceuticals with similar occurrence patterns in 395 
surface water. For example, in our dataset for all the rivers where both diclofenac and 396 
carbamazepine were measured, they were positively detected 90% of the time. Similar patterns 397 
were also observed for pharmaceuticals that were not detected when measured concurrently. 398 
Our model provides a probabilistic estimate of positively detecting unstudied pharmaceuticals 399 
in rivers (Figure 4), which can complement existing mechanistic/process-based models such as 400 
those proposed by (Huggett et al., 2003; Kumar and Xagoraraki, 2010; Roos et al., 2012) to 401 
choose the pharmaceuticals needed to be included in a study. For example, if diclofenac is 402 
positively detected in a river, it might not be useful to measure carbamazepine in the same 403 
river as it is very likely to be positively detected. A cross-validation exercise (results not shown) 404 
suggests that, by grouping pharmaceuticals with similar co-occurrence pattern in rivers, we can 405 
make reasonable predictions on the presence/absence of all the pharmaceuticals within a 406 
group by performing field measurement of few ‘selected’ pharmaceuticals, a very useful 407 
feature given the high costs associated with measuring concentration of these pharmaceuticals. 408 
As an example, we provide estimates of the probability of detecting few selected 409 
pharmaceuticals that were not studied in River Colorado, Elbe and Rhine (Table 1).Indeed 410 
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Diclofenac was positively detected in all the water ways of Elbe River catchment (Marsik et al., 411 
2017; Meyer et al., 2016). Although this example is for illustrative purposes, the goal is to 412 
highlight the applicability of statistical analyses of big pharmaceutical datasets in providing 413 
useful information on environmental pharmaceutical contamination. We encourage 414 
researchers to validate the robustness and accuracy of the method by comparing the 415 
pharmaceutical detection rates to our model output. We hope that this paper would motivate 416 
users to use our method or develop newer statistical methods that can be applied to the 417 
emerging field of environmental pharmaceutical contamination. Our analysis has highlighted 418 
and confirmed some of the patters (effect of population, consumption patterns) that have been 419 
suggested before but never explored globally. 420 
As the number of studies measuring pharmaceuticals in environmental matrix using 421 
standardized protocol, composite sampling and concurrent measurements of WWTP and 422 
receiving water is increasing rapidly, for example see (Challis et al., 2018; Cui et al., 2019; Grill 423 
et al., 2016; Kay et al., 2017), in future we plan to perform similar analysis using concentration 424 
rather than presence/absence data yielding results that are more useful from eco-toxological 425 
and policy point of view. Such analysis will be especially appropriate for comparing river basins 426 
within a country as in-country variation in pharmaceutical consumption behavior and WWTP 427 
efficiency is likely to be smaller than between country variation. We believe that combining 428 
process-based rankings with results from sophisticated statistical model would maximize the 429 
information that can be obtained on the toxicity of pharmaceuticals in different environmental 430 
matrices and could help in developing sustainable strategies to minimize the effects of 431 
pharmaceuticals on aquatic ecosystems.  432 
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5. Conclusions 433 
Previous works have suggested the presence of numerous pharmaceuticals from a wide 434 
spectrum of therapeutic classes in environmental waters (Beek et al., 2016; Daughton, 2001; 435 
Hughes et al., 2013; Loos et al., 2010). However, to our knowledge, none of them except (Loos 436 
et al., 2010) have conducted a systematic assessment of the detection rate of pharmaceuticals 437 
across multiple rivers. Our meta-analysis highlights the differences in the detection rate of 112 438 
pharmaceuticals and their variation across Asia, Europe and North America. We identify some 439 
of the possible factors including consumption rate, local hydrology and population that could 440 
be driving this pattern. Whereas we could detect a first order relationship between 441 
pharmaceutical detection rates and pharmaceutical use, the effect of hydrological factors could 442 
not be resolved in this analysis. Importantly, our approach informs the probability of detecting 443 
unanalyzed pharmaceuticals and supports analyte prioritization for future. 444 
Many of our findings have been suggested before, however here we show these empirically 445 
using a large dataset analyzed within a statistical framework. Future analysis could leverage 446 
much larger datasets and more sophisticated statistical techniques to acquire more detailed 447 
and improved information on pharmaceutical contamination in surface water. 448 
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Figure 1. Schematic representing simultaneous clustering of 10 (hypothetical) rivers and 14 686 
(hypothetical) pharmaceuticals studied on those rivers. (a): Detection rate (how often a pharmaceutical 687 
was positively detected when analyzed for) of the 14 pharmaceuticals (columns) measured across 10 688 
rivers (rows) arranged in alphabetical order. Pharmaceuticals that are not studied in a river are shown as 689 
blank. (b) Rearranged blocks of pharmaceuticals and rivers that exhibit high degree of similarity. The 690 
SBM divides the 14 pharmaceuticals in 4 clusters (A to D, separated by blue vertical lines). The algorithm 691 
also divides the 10 rivers in three groups (1 to 3, separated by magenta horizontal lines). Each color 692 
represents a river-pharmaceutical block. As an example,  “pharmaceutical cluster A – river group 1” 693 
reveals that the detection rates of pharmaceuticals in cluster A have the lowest detection rates for river 694 
group 1 and “pharmaceutical cluster D – river group 3” reveals that the detection rates of 695 
pharmaceuticals in cluster D have the highest detection rates for river group 3. (c) The probability of 696 
positively detecting an unstudied pharmaceutical (for example, pharma 8 at river 1) is 0.9 (as they 697 




Figure 2. RCI of the rivers grouped by the total number of measurements on the river. The color palette 700 





Figure 3. Detection rate of the 112 pharmaceuticals (columns) studied across the 64 rivers (rows). White 704 
square represents pharmaceuticals that were not studied at that river. The matrix has been ordered 705 
according to the river-pharmaceutical block. Rows 1-9, 10-21, 22-35, 36-60 and 61-64 represents river 706 
groups 1,2,3,4, and 5 (partitioned by magenta lines). Columns 1-67, 68-81, 82-85, 86-91, 92-103 and 707 
104-112 represents pharmaceutical clusters A, B, C, D, E and F (partitioned by blue lines). The 708 
pharmaceuticals clusters are arranged according to the detection rate. Each rectangle enclosed by the 709 
magenta and blue lines is a pharmaceutical-river block. Blocks “A–4” and “E–3” are highlighted (lightly 710 
shaded) for illustrative purposes. Mean detection rate (and the 95% credible interval) for each river-711 
pharmaceutical block is shown in figure 4. The name of the rivers in Asia are highlighted in (blue), 712 





Figure 4. Mean probability (shown by red circle) and 95% credible interval (Shown as error bar) of 716 





Figure 5. Detection rate of pharmaceuticals in rivers, WWTP-effluents and WWTP-influents. (a): 720 
pharmaceuticals in clusters A to C in WEOG, (b):  pharmaceuticals in clusters A to C in Asia, (c): 721 
pharmaceuticals in clusters D to F in WENA and (d):  pharmaceuticals in clusters D to F in Asia.  722 
  723 




Figure 6. Relationship between river contamination index (RCI) and population density for the rivers 726 
analyzed in this study. Population density has been divided into 5 sub-classes (<50, 50-100, 100-200, 200-727 
500 and >500 persons/square kilometer). Correlation between population density and RCI are 728 




  733 
36 
 
Table 1: Mean probability and 95% credible interval (values in bracket) of the detection rate of selected 734 
pharmaceuticals for River Colorado, Rhine and Elbe. 735 
River Pharmaceutical Probability of detection 
Colorado Estradiol 35% (20-50%) 
Colorado Ciprofloxacin 65% (60-85%) 
Colorado Erythromycin 90% (80-100%) 
Colorado Diclofenac 98% (95-100%) 
Rhine Estradiol 10% (0-20%) 
Rhine Ciprofloxacin 40% (20-60%) 
Rhine Erythromycin 60% (40-80%) 
Rhine Diclofenac 90% (80-95%) 
Elbe Estradiol 0% (0-5%) 
Elbe Ciprofloxacin 3% (0-10%) 
Elbe Erythromycin 95% (65-100%) 
Elbe Diclofenac 97% (95-100%) 
 736 
